Sizzling Stock Picks

[goodibag]

OMHE_Marijuana_based_Pain_Medicine_Starting_FDA_Registration_QB_Uplist


12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here

MIAMI, FL, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Omni Health, Inc., (OTC: OMHE), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and biotech engineering, today announced its plan already in motion to create a drug candidate compelling to Big Pharma.

Based on four decades of exemplary care, Omni Health has started the process of reformulating its most successful proprietary formularies to include cannabidiol (CBD) and commence its FDA Medical Devices registration for topical pain analgesic. It is Omni Health’s intent to capitalize on a significant potential for cannabinoid bio therapeutics to transform the treatment of chronic pain and other debilitating conditions, and bring a product to the market with a strong demand and reimbursable under government payors and major insurance plans.

More High-Tech Announcements are on the way…


OMHE PPS Ready to Rise to $1